Chronoscale Holdings Corp quarterly report, Q1 FY2013

Filing summary

Reporting period and identity: This is a quarterly report for the three months ended June 30, 2012, filed by PN Med Group Inc., a Nevada development-stage company planning to distribute medical supplies and equipment in Chile. The request metadata names Chronoscale Holdings Corp.; that does not match the registrant identified in the filing. The company reports a March 31 fiscal year-end.

Financial performance and position

  • Revenue: $0 for the quarter and $0 from inception on January 30 through June 30, 2012. The company states it had not commenced operations.
  • Expenses and loss: Quarterly operating expenses and net loss were both $4,895: professional fees $4,846, bank fees $37, and miscellaneous expenses $12. Cumulative net loss since inception was $9,552. Basic and diluted loss per share was reported as $(0.00); weighted-average shares were 5,000,000.
  • Margins: Not meaningful with no revenue.
  • Cash flow: Quarterly operating cash use was $8,645; financing provided $5,431; cash declined $3,214 to $5,229. From inception, operating cash use was $8,802 and financing provided $14,031. No investing cash flow was reported.
  • Liquidity: At June 30, cash and total current assets were $5,229, versus current liabilities of $9,781, implying a $4,552 working-capital deficit. Total stockholders’ equity was a deficit of $4,552, compared with positive equity of $343 at March 31.
  • Debt and obligations: $9,031 was owed to a shareholder/officer, up from $3,600 at March 31. The loans are unsecured, non-interest-bearing, and due on demand. Accrued expenses were $750, compared with $4,500 at March 31. No bank credit lines were reported.
  • Other: The company reported no income-tax provision, no interest or income taxes paid, and no recognized deferred tax asset after a full valuation allowance. Approximately $9,600 of net operating loss carryforwards were reported, subject to potential limitations.

Changes, outlook, and risks

  • Compared with March 31, cash fell by $3,214, shareholder loans rose by $5,431, accumulated losses increased by $4,895, and equity moved from a $343 surplus to a $4,552 deficit. The filing provides no prior-year comparable-quarter operating results; the company was incorporated in January 2012.
  • Management expects to fund near-term operations with existing funds and further advances or securities issuances, and says those sources are expected to cover approximately the next three months. It also says additional funds will be needed within twelve months and identifies no specific financing plan or arranged future equity financing. Additional equity or convertible debt could dilute shareholders; financing may be unavailable or on unacceptable terms.
  • The filing identifies substantial doubt about the company’s ability to continue as a going concern. It has no revenue, limited working capital, and expects dependence on additional capital. There is no assurance it can raise funds or achieve financial viability.
  • Management reported disclosure controls and procedures were not effective as of June 30, 2012. It reported no material change in internal control over financial reporting during the quarter.
  • The company reported no material subsequent events through issuance, no known pending or threatened legal proceedings, and no material off-balance-sheet arrangements. An officer provided office services without charge, with no obligation to continue.
  • The business plan calls for importing products from manufacturers in China and distributing them in Chile. Risks include startup execution, inventory and marketing funding needs, dependence on external financing, and the officer’s ability to continue providing office services.

Key facts for investors to verify

  1. Confirm the registrant’s identity: the supplied metadata says Chronoscale Holdings Corp., but the filing names PN Med Group Inc.
  2. Verify the filing period and timing: the report covers the quarter ended June 30, 2012 and is signed November 2, 2012.
  3. Assess cash runway and the availability and terms of funding, including whether shareholder loans due on demand will be repaid or extended.
  4. Evaluate the going-concern uncertainty, absence of revenue, and management’s ability to launch operations and secure customers and inventory.
  5. Consider the disclosed ineffective controls and any related reporting or governance implications.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.